Synlogic Corp (SYBX): שווי כולל של נכסי החברה

Synlogic, Inc. (SYBX) generates revenue by creating synthetic probiotics for the therapy of metabolic disorders through partnerships with pharmaceutical behemoths. This chart of the share price illustrates total assets, which currently stand at 18.67. However, the experimental approach and rapid capital burn create significant risks, while the current stage of winding down the business requires strict control of remaining funds and the monetization of patents.

For Synlogic, Inc. (SYBX), which develops innovative drugs based on modified bacteria, resource dynamics are critical when scaling therapies for metabolic disorders. This total asset calculation is based on a reverse return on assets (ROA) analysis, combining liabilities and equity to assess management's ability to effectively expand the business's material base without compromising capital efficiency.